Nachrichten zur Eli Lilly & Co. Aktie

Eli Lillys obesity drug now available in U.S. pharmacies

Eli Lillys recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured…

Eli Lillys obesity drug now available in U.S. pharmacies By Reuters

Eli Lillys obesity drug now available in U.S. pharmacies…

: Eli Lilly’s new obesity drug Zepbound added to major PBM formularies as it hits pharmacy shelves

Eli Lilly & Co. LLY said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit…

How every Club stock performed over the past 10 Decembers, a historically strong month

Over the past decade, December been especially kind to Broadcom (AVGO) and Eli Lilly (LLY).…

Pro Research: Wall Street takes on Eli Lillys prospects By Investing.com

Pro Research: Wall Street takes on Eli Lillys prospects…

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this…

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15 By Reuters

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15…

Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?

Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…

Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk? @themotleyfool #stocks $LLY $NVO

Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…

US FDA gives second approval to Eli Lillys drug for type of blood cancer

Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca,…

Why Pfizers latest stumble in the obesity market is a boon for Eli Lilly

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and thats good news for…

Why investors should stick with Eli Lilly

The Investing Club holds its Morning Meeting every weekday at 10:20 a.m. ET.…

1 Underrated Reason to Buy Eli Lilly Stock @themotleyfool #stocks $LLY

Eli Lilly has a well-rounded business that can be a good fit for all types of investors.…

Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low

Investors’ have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight…

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

…

LEXX: GLP-1s’ Sweet Opportunity

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with…

Here are Thursdays biggest analyst calls: Nvidia, Apple, Eli Lilly, Salesforce, Snowflake, Snap, Pinterest & more

Here are the biggest calls on Wall Street on Thursday.…

Eli Lillys Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the…

Eli Lillys Weight-Management Drug Outperformed Ozempic. Is It Time to Buy? @themotleyfool #stocks $LLY $NVO

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the…

Cramer says Eli Lilly is the only drug stock that’s working as it differentiates itself among competitors

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

…

Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego

The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and…

3 Large Drug Stocks That Have Outperformed Industry YTD

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.…

: Eli Lilly’s Mounjaro three times more effective than Ozempic for weight loss, real-world study finds

Eli Lillys Mounjaro is significantly more effective than Novo Nordisks Ozempic in producing weight loss, a real-world study found…

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says

Patients on Eli Lillys Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to…

Synthetic Hormones Market Analysis Report 2023-2033, Featuring Profiles of Eli Lilly, Pfizer, Ferring, Merck, Novo Nordisk, Bayer, Novartis and More

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Synthetic Hormones Market: Focus on Product Type, Application, Route…

The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce

Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.…

Novo Nordisk: Eli Lillys Zepbound Approval Is Not A Threat To Valuation

…

Top Stock Reports for Eli Lilly, Accenture & The TJX Companies

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN)…

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3…

Will Eli Lilly Be Worth More Than Tesla by 2027?

Its a lot more likely than it sounds.…

Will Eli Lilly Be Worth More Than Tesla by 2027? @themotleyfool #stocks $LLY $TSLA

Its a lot more likely than it sounds.…

Eli Lilly (LLY) Stock Outperforms Industry YTD: Heres Why

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimers. Mounjaro and Zepbound are expected to…

Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldnt Count Out This Healthcare Giant @themotleyfool #stocks $AZN

Could AstraZeneca be an under-rated buy right now?…

dpa-AFX ProFeed